The Role of Biofilm Formation in Candida spp. Pathogenesis

Conny Riana Tjampakasari; Shalfa Hisana Wibowo

doi:10.55927/fjst.v4i10.262

Authors

Conny Riana Tjampakasari Universitas Indonesia
Shalfa Hisana Wibowo Universitas Indonesia

DOI:

https://doi.org/10.55927/fjst.v4i10.262

Keywords:

Biofilm, Candida spp., Pathogenicity

Abstract

Biofilms are defined as structured communities of microorganisms that are embedded in a self-produced matrix of extracellular polymeric substances and are typically attached to biological and non-biological surfaces. The formation of biofilms is a survival strategy adopted by microorganisms to withstand various environmental stresses, and biofilms can act as a reservoir for persistent sources of infection. Biofilm-forming microorganisms are known to be involved in a wide range of human infections that are challenging to treat and have severe health consequences. Candida spp. is one of the microorganisms capable of forming biofilms. As a commensal, Candida spp. can be found on the skin, mucosal tissues, upper respiratory tract, genitourinary tract, and gastrointestinal tract. In healthy individuals, the growth of Candida spp. is controlled by the immune system and the presence of other microbiota. However, when one of these barriers is disrupted, Candida spp. can behave as pathogens, causing superficial to systemic infections. Notably, Candida spp. biofilms often exhibit characteristics that render them resistant to several antifungal drugs, which has significant clinical implications and contributes to higher mortality rates. Therefore, this paper will primarily discuss the role of biofilms in modulating the pathogenicity of Candida spp

References

1. Mahami T. Biofilm-associated infections : public health implications. 2011;2(11):375–81.

2. Gulati M, Nobile CJ. Candida albicans biofilms: development, regulation, and molecular mechanisms. Microbes Infect [Internet]. 2016;18(5):310–21. Available from: http://dx.doi.org/10.1016/j.micinf.2016.01.002

3. Berhe N, Tefera Y, Tintagu T. Review on biofilm formation and its control options. Int J Adv Res Biol Sci [Internet]. 2017;4(4):37–43. Available from: http://dx.doi.org/10.22192/ijarbs.2017.04.04.006

4. Wall G, Montelongo-Jauregui D, Vidal Bonifacio B, Lopez-Ribot JL, Uppuluri P. Candida albicans biofilm growth and dispersal: contributions to pathogenesis. Curr Opin Microbiol [Internet]. 2019;52:1–6. Available from: https://doi.org/10.1016/j.mib.2019.04.001

5. Nobile CJ, Johnson AD. Candida albicans Biofilms and Human Disease. Annu Rev Microbiol. 2015;69(1):71–92.

6. Tsui C, Kong EF, Jabra-Rizk MA. Pathogenesis of Candida albicans biofilm. Pathog Dis. 2016;74(4):ftw018.

7. Rodríguez-Cerdeira C, Gregorio MC, Molares-Vila A, López-Barcenas A, Fabbrocini G, Bardhi B, et al. Biofilms and vulvovaginal candidiasis. Colloids Surfaces B Biointerfaces. 2019;174(May 2018):110–25.

8. Mora-Montes HM, Lopes-Bezerra LM. Current progress in medical mycology. Current Progress in Medical Mycology. Cham, Switzerland: Springer International Publishing; 2017. 1–425 p.

9. Walsh TJ, Hayden RT, Larone DH. Larone’s Medically Important Fungi. Larone’s Medically Important Fungi. Washington, DC: ASM Press; 2018.

10. Dabiri S, Shams-Ghahfarokhi M, Razzaghi-Abyaneh M. Comparative analysis of proteinase, phospholipase, hydrophobicity and biofilm forming ability in Candida species isolated from clinical specimens. J Mycol Med [Internet]. 2018;28(3):437–

42. Available from: https://doi.org/10.1016/j.mycmed.2018.04.009

11. Gupta P, Sarkar S, Das B, Bhattacharjee S, Tribedi P. Biofilm, pathogenesis and prevention—a journey to break the wall: a review. Arch Microbiol. 2016;198(1):1– 15.

12. Vasudevan R. Biofilms: Microbial Cities of Scientific Significance. J Microbiol Exp. 2014;1(3).

13. Fanning S, Mitchell AP. Fungal biofilms. PLoS Pathog. 2016;8(4):1–4.

14. Cakiroglu Y, Caliskan S, Doger E, Ozcan S, Caliskan E. Does removal of CU-IUD in patients with biofilm forming candida really maintain regression of clinical symptoms? J Obstet Gynaecol (Lahore) [Internet]. 2015;35(6):600–3. Available from: http://dx.doi.org/10.3109/01443615.2014.986442

15. Taff HT, Mitchell KF, Edward JA, Andes DR. Mechanisms of Candida biofilm drug resistance. Future Microbiol. 2013;8(10):1325–37.

16. Mitchell KF, Taff HT, Cuevas MA, Reinicke EL, Sanchez H, Andes DR. Role of matrix β-1,3 glucan in antifungal resistance of non-albicans Candida biofilms. Antimicrob Agents Chemother. 2013;57(4):1918–20.

17. Martins M, Henriques M, Lopez-Ribot JL, Oliveira R. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses. 2012;55(1):80–5.

18. Montanaro L, Poggi A, Visai L, Ravaioli S, Campoccia D, Speziale P, et al. Extracellular DNA in biofilms. Int J Artif Organs. 2011;34(9):824–31.

19. Nobile CJ, Fox EP, Nett JE, Sorrells TR, Mitrovich QM, Hernday AD, et al. A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell [Internet]. 2012;148(1–2):126–38. Available from: http://dx.doi.org/10.1016/j.cell.2011.10.048

20. Xie Z, Thompson A, Sobue T, Kashleva H, Xu H, Vasilakos J, et al. Candida albicans biofilms do not trigger reactive oxygen species and evade neutrophil killing. J Infect Dis. 2012;206(12):1936–45.

21. Dwivedi P, Thompson A, Xie Z, Kashleva H, Ganguly S, Mitchell AP, et al. Role of Bcr1-activated genes Hwp1 and Hyr1 in Candida albicans oral mucosal biofilms and neutrophil evasion. PLoS One. 2011;6(1).

22. Nett JE. The host’s reply to Candida biofilm. Pathogens. 2016;5(1).

23. Cateau E, Berjeaud JM, Imbert C. Possible role of azole and echinocandin lock solutions in the control of Candida biofilms associated with silicone. Int J Antimicrob Agents [Internet]. 2011;37(4):380–4. Available from: http://dx.doi.org/10.1016/j.ijantimicag.2010.12.016

24. Toulet D, Debarre C, Imbert C. Could liposomal amphotericin B (L-AMB) lock solutions be useful to inhibit Candida spp. biofilms on silicone biomaterials? J Antimicrob Chemother. 2012;67(2):430–2.

25. Bonne S, Mazuski JE, Sona C, Schallom M, Boyle W, Buchman TG, et al. Effectiveness of Minocycline and Rifampin vs Chlorhexidine and Silver Sulfadiazine-Impregnated Central Venous Catheters in Preventing Central Line- Associated Bloodstream Infection in a High-Volume Academic Intensive Care Unit: A before and after Trial. J Am Coll Surg [Internet]. 2015;221(3):739–47. Available from: http://dx.doi.org/10.1016/j.jamcollsurg.2015.05.013

26. Villard N, Seneviratne C, Tsoi JKH, Heinonen M, Matinlinna J. Candida albicans aspects of novel silane system-coated titanium and zirconia implant surfaces. Clin Oral Implants Res. 2015;26(3):332–41.

27. Morales DK, Grahl N, Okegbe C, Dietrich LEP, Jacobs NJ, Hogan DA. Control of Candida albicans metabolism and biofilm formation by Pseudomonas aeruginosa phenazines. MBio. 2013;4(1):1–9.

28. Cavalheiro M, Teixeira MC. Candida Biofilms: Threats, challenges, and promising strategies. Front Med. 2018;5(FEB):1–15.